ASMB · Assembly Biosciences, Inc. · Metrics
$20.57
+0.27 (+1.33%)
At close · Oct 28
Return incl. dividend (before tax)
Market Cap
$418.82M
Shares
20.36M
Volume · Oct 28
142.69K
Avg daily vol (3M)
287.69K
ASMB metrics
66 of 122 screener metrics currently available.
Market overview
2 metricsShare price
$20.57
Market cap
$418.82M
Price action
20 metricsPrice change (1W)
-4.2%
Price change (30D)
-14.0%
Price change (3M)
-20.6%
Price change (6M)
-24.8%
Price change (YTD)
-40.3%
Price change (1Y)
-31.9%
Trailing year
Price change (5Y)
—
52-week high
$38.50
52-week low
$19.67
Change from 52-week high
-47.3%
Change from 52-week low
+3.2%
Annualized volatility
58.8%
Annualized volatility (3M)
62.3%
Beta
1.4
RSI (14D)
34.9
Price vs SMA 50
-24.5%
Price vs SMA 200
-25.8%
Avg volume (3M)
286,826
Relative volume
0.7
Average dollar volume
$7.91M
Company
3 metricsSector
Healthcare
Industry
Biotechnology
Shares outstanding
20.36M
Valuation
12 metricsP / E (TTM)
16.8
Trailing earnings · reciprocal yield 6.0%
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
5.5×
reciprocal yield 18.1%
P / book
1.4
reciprocal yield 73.9%
FCF yield
-9.3%
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
0.0%
Historical valuation
8 metricsP / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—
Dividends & buybacks
7 metricsDividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—
Earnings calendar
2 metricsNext earnings
—
Last earnings
2026-04-17
Profitability
9 metricsGross margin
—
Operating margin
-11.8%
Trailing 12 months
Net margin
-0.1%
Gross profit (TTM)
—
Operating profit (TTM)
−$8.80M
Net income (TTM)
−$42,000
Trailing 12 months
Diluted EPS (TTM)
$1.21
FCF margin
-51.5%
Effective tax rate
—
Growth
11 metricsRevenue growth YoY
+38.9%
Year over year
Net income growth YoY
—
Revenue (TTM)
$74.84M
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+146.3%
Year over year · more shares
Revenue CAGR (3Y)
—
Revenue CAGR (5Y)
-1.8%
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—
Quality
14 metricsReturn on equity
0.0%
Return on assets
0.0%
Debt / equity
—
Current ratio
14.0
EBITDA (TTM)
−$8.69M
Free cash flow (TTM)
−$38.57M
Quick ratio
14.0
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Cash & equivalents
$32.29M
Total assets
$330.83M
Total debt
—
Cash flow & spend
7 metricsOperating cash flow (TTM)
−$38.48M
Capital expenditures (TTM)
$85,000
R&D (TTM)
$63.65M
SG&A (TTM)
—
Stock compensation (TTM)
$6.66M
R&D / revenue
85.0%
Stock compensation / revenue
8.9%
Ownership (13F)
9 metrics13F filers
93
13F filer change QoQ
+18
Institutional ownership
92.3%
Conviction holders (share of 13F filers)
3.3%
Crowding (high-turnover and private-fund holders)
—
Private-fund adviser ownership
—
Active holders' share change QoQ
+28.6%
Holder tenure
5.3
Price vs estimated holder cost
+7.6%
Ownership (registered funds)
1 metricsIndex-fund ownership
5.6%
Short interest
3 metricsShort interest
14.3%
Latest settlement · 11.1 days to cover
Days to cover
11.1d
Short-squeeze score
70 / 100
Insider activity
2 metricsNet insider buying (90D)
—
Insider-sentiment score
—
Risk flags
1 metricsGoing concern
—